HAVN Life Sciences Inc. (OTCPK: HAVL.F)
Health Care · Biotechnology · CA
$—
— today · — 1Y
HAVN Life Sciences Inc. (OTCPK: HAVL.F) operates in the Biotechnology industry within the Health Care sector. The company is valued at $29.00.
trading between 0.00 and 0.00.
Tweenvest scores HAVN Life Sciences Inc. across four factors: quality 18/100. Its strongest factor is quality.
HAVL.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.00
- Revenue (TTM)
- $440.11K
- P/E
- —
- EPS
- -2.20
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 28.65M
- Employees
- —
- Next earnings
- —
About HAVN Life Sciences Inc.
HAVN Life Sciences Inc. is a biotechnology firm dedicated to the research and creation of psychotropic compounds sourced from flora and fungi. The company's expertise includes devising standardized and quality-assured extraction techniques for psychoactive substances, particularly from Psilocybe mushrooms, to isolate key compounds such as psilocybin, psilocin, and baeocystin. Furthermore, it develops natural health remedies using non-regulated ingredients. This Canadian company, founded in 2020, is headquartered in Richmond.
- ISIN
- CA4196213058
- Founded
- 2020
- Listed since
- Sep 8, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €894.20 | +1.71% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.